Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06809400 · ClinicalTrials.gov registry record · Phase 1
A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease
A Phase 1 study of Parkinson Disease, sponsored by Eli Lilly and Company.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
- 14
- Study locations
NCT06809400 is a Phase 1 study of Parkinson Disease that is actively recruiting participants, run by Eli Lilly and Company. The registered enrollment target is 127 participants, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The trial reports 14 study locations across 6 states.
The verdict
NCT06809400, a Phase 1 study of Parkinson Disease, is actively recruiting participants, sponsored by Eli Lilly and Company.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
- 14
- Study locations
Study Summary
The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
Conditions Studied
Interventions
- DRUG Placebo
- DRUG LY4006896
Study Locations (14)
Florida
- K2 Medical Research, LLC - Maitland
- Aqualane Clinical Research - Naples
- Charter Research - Orlando
- Progressive Medical Research - Port Orange
- K2 Medical Research, LLC - The Villages
- Charter Research - The Villages
California
- Collaborative Neuroscience Network - CNS - Los Alamitos
- Collaborative Neuroscience Network - CNS - Los Alamitos
Washington
- Evergreen Health Research - Kirkland
- Inland Northwest Research - Spokane
Other
- P-One Clinic - Hachiōji
- Oita University Hospital - Yufu
Michigan
- QUEST Research Institute - Farmington Hills
Texas
- PPD Development, LP - Austin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2025-02-18 |
| Est. Completion | 2028-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06809400
The ClinicalTrials.gov registry entry for NCT06809400 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,326-participant average among 297 other Parkinson Disease trials with a reported enrollment target (98% lower). The listed sponsor is Eli Lilly and Company, which has 1,341 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Parkinson Disease appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT06809400 reports 14 study locations spanning 6 distinct geographic areas - top geographies include Florida, California, Washington.
Frequently Asked Questions
What is clinical trial NCT06809400 about?
NCT06809400 is a clinical study titled "A Study of LY4006896 in Healthy Participants and Participants With Parkinson's Disease". The purpose of this study is to generate evidence of the safety, tolerability, and pharmacokinetics/pharmacodynamics of IV LY4006896 compared with placebo in healthy participants and participants with Parkinson's disease.
What is the current status of trial NCT06809400?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2025-02-18. Estimated completion is 2028-01.
What conditions does trial NCT06809400 study?
This clinical trial studies the following conditions: Parkinson Disease.
What interventions are being tested in trial NCT06809400?
The interventions under investigation include: Placebo (DRUG), LY4006896 (DRUG).
Who is sponsoring clinical trial NCT06809400?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06809400 being conducted?
This trial has 14 study locations across California, Florida, Michigan, Texas, Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Parkinson Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Treating Parkinson's Disease Through Transplantation of Autologous Stem Cell-Derived Dopaminergic Neurons
RECRUITING · Phase 1
-
First-in-Human Single and Multiple Dose of HL-400
RECRUITING · Phase 1
-
Phase 2 Trial of Tributyrin in People With Parkinson's Disease and Cognitive Impairments
RECRUITING · Phase 1
-
[18F]F-DOPA Imaging in Patients With Autonomic Failure
RECRUITING · Phase 1
-
A Study to Assess the Safety of BMS-984923 Compared to Placebo, in People With Parkinson's
RECRUITING · Phase 1
-
The University of Alabama At Birmingham (UAB) Neuroinflammation in Parkinson's Disease-TSPO- Positron Emission Tomography (PET) Substudy
RECRUITING · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.